Evaluation of Intravenous Dalbavancin for Peritonitis

Evaluation of Intravenous Dalbavancin for Treatment of Peritonitis in Peritoneal Dialysis Patients

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04624451

Enrollment

Registered

2020-11-10

Start date

2020-06-01

Completion date

2024-01-31

Last updated

2024-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritonitis, Peritonitis Bacterial

Brief summary

This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.

Interventions

DRUGDalbavancin

Dalbavancin 1500 mg intravenously x 1 dose

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients \> 18 years of age actively receiving peritoneal dialysis diagnosed with a gram + peritonitis determined to be a good candidate for dalbavancin treatment by the attending nephrology attending.

Exclusion criteria

Patients with contraindications to dalbavancin therapy

Design outcomes

Primary

Measure	Time frame	Description
Clinical cure	14 days	resolution of signs and symptoms (e.g. abdominal pain), bacterial eradication, reduction in clinical markers (e.g. peritoneal fluid findings, CRP, etc), and return of peritoneal dialysis functionality

Secondary

Measure	Time frame	Description
Treatment emergent adverse events	14 days	Occurrence of any adverse events

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026